Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pustular Palmoplantar Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Pustular Palmoplantar Psoriasis. Displaying page 1 of 1.
    EudraCT Number: 2013-003086-34 Sponsor Protocol Number: CAIN457A3301 Start Date*: 2013-12-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Ind...
    Medical condition: Moderate to severe chronic palmoplantar pustular psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037158 Psoriasis palm & soles LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004573-40 Sponsor Protocol Number: 1368-0015 Start Date*: 2017-04-28
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI ...
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050185 Palmoplantar pustulosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000189-41 Sponsor Protocol Number: 1368-0024 Start Date*: 2020-07-08
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Prematurely Ended) PL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003078-28 Sponsor Protocol Number: 1368-0016 Start Date*: 2019-07-01
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to ...
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) CZ (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022843-39 Sponsor Protocol Number: ATN117221 Start Date*: 2011-04-08
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment
    Medical condition: Palmo-Plantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10050185 Palmoplantar pustulosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004451-20 Sponsor Protocol Number: DER201702 Start Date*: 2019-07-17
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)
    Medical condition: Adult men and women with palmoplantar pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003029-31 Sponsor Protocol Number: RIST4721-202 Start Date*: 2022-04-27
    Sponsor Name:Aristea Therapeutics Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
    Medical condition: Palmoplantar Pustulosis (PPP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003922-70 Sponsor Protocol Number: TUD-PPPDD1-021 Start Date*: 2007-11-28
    Sponsor Name:Technische Universität Dresden
    Full Title: Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP)
    Medical condition: moderate to severe palmoplantar pustular psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004022-15 Sponsor Protocol Number: ANB019-003 Start Date*: 2020-04-21
    Sponsor Name:AnaptysBio Inc
    Full Title: A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
    Medical condition: Palmoplantar pustulosis (PPP)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003206-58 Sponsor Protocol Number: CNTO1959PSO3013 Start Date*: 2019-06-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
    Medical condition: Palmoplantar non-Pustular Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003600-23 Sponsor Protocol Number: APRICOT Start Date*: 2016-04-01
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies
    Medical condition: Acral Pustular Psoriasis, specifically but not limited to Palmo-Plantar Pustulosis will be the target population for therapeutic intervention with Anakinra in this study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006931-25 Sponsor Protocol Number: N/A Start Date*: 2022-03-24
    Sponsor Name:Bispebjerg and Frederiksberg Hospital, University of Copenhagen
    Full Title: Efficacy and safety of oral roflumilast in the treatment of palmoplantar pustulosis – a randomised controlled trial
    Medical condition: Palmoplantar pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037158 Psoriasis palm & soles LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:52:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA